What is Amador Bioscience?
Amador Bioscience operates as a Contract Research Organization (CRO) specializing in global-standard quantitative clinical pharmacology, GLP/GCLP bioanalysis, clinical research, and regulatory filing services. Established in 2018 and headquartered in Pleasanton, California, the company serves leading biopharmaceutical firms. Its comprehensive service offering positions it as a key partner for drug development and regulatory approval processes, enabling clients to navigate complex scientific and regulatory landscapes.
How much funding has Amador Bioscience raised?
Amador Bioscience has raised a total of $60M across 1 funding round:
Series B
$60M
Series B (2021): $60M with participation from GL Ventures, CMB International Capital, Co-win Ventures, Sequoia Capital, and MSA Capital
Key Investors in Amador Bioscience
GL Ventures
GL Ventures, LLC is a consulting firm that collaborates with entrepreneurs, CEOs, and board members to develop growth strategies and facilitate significant changes within their organizations, specializing in assisting under-capitalized and emerging companies.
CMB International Capital
CMB International Capital Corporation Limited ("CMBI") is a wholly-owned subsidiary of China Merchants Bank ("CMB"), providing comprehensive corporate finance services including Hong Kong IPO sponsorship and underwriting, share placement, and financial advisory.
Sequoia Capital
Sequoia Capital in India manages funds capitalized at close to USD 1.4 billion and invests across venture, growth, and late stage opportunities, taking a long-term view and playing an active, value-added partner role to entrepreneurs.
What's next for Amador Bioscience?
The substantial enterprise-level funding indicates Amador Bioscience is poised for significant scaling and expansion. This strategic investment will likely fuel advancements in its service capabilities, potentially broadening its global reach and enhancing its technological infrastructure. The company's focus on critical areas like clinical pharmacology and bioanalysis suggests a strategic intent to solidify its position as a leader in supporting biopharmaceutical innovation and accelerating the path to market for new therapies.
See full Amador Bioscience company page
